MUAMU
VKTX icon

Mitsubishi UFJ Asset Management (UK)’s Viking Therapeutics VKTX Stock Holding History

Mitsubishi UFJ Asset Management (UK)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$325K – 107
2026
Q1 		$325K Buy
10,000
+8,000
+400% +$257K 0.17% 85
2025
Q4 		$70K Hold
2,000
– – 0.03% 83
2025
Q3 		$53K Buy
+2,000
New +$59.7K 0.03% 100

Other funds holding VKTX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
IFWM
Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Mitsubishi UFJ Asset Management (UK)'s VKTX Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management (UK) sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 10,000 shares — an estimated $325K sold.

Mitsubishi UFJ Asset Management (UK) first reported a position in VKTX in Q3 2025 and held it in 3 quarters. The position peaked at $325K in Q1 2026. 116 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Mitsubishi UFJ Asset Management (UK) reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management (UK) sold 10,000 Viking Therapeutics shares in Q2 2026, an estimated $325K.
  • Mitsubishi UFJ Asset Management (UK) first reported a position in Viking Therapeutics in Q3 2025 and held it in 3 quarters.
  • Mitsubishi UFJ Asset Management (UK)'s Viking Therapeutics position peaked at $325K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management (UK)'s 13F filing for Q2 2026, filed 28 Jul 2026.